Navigation Links
Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:9/16/2009

EAST BRUNSWICK, N.J. Sept. 16 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that on September 14, 2009, the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) received by Savient on July 31, 2009 regarding the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.

Based on the results of this meeting with the FDA, Savient believes that the FDA supports its approach to resolve all issues cited in the CRL. The meeting also confirmed that the FDA does not expect further clinical trials to be required as a result of Savient's reversion to the original manufacturing process to produce the Phase 3 clinical trial material for KRYSTEXXA, provided that no significant differences are observed between the material produced with the validated Phase 3 process and the Phase 3 clinical trial material. Savient, therefore, continues to believe that it can meet its previously discussed timeline of filing the resubmission in response to the CRL in early 2010.

"We are encouraged by the FDA's continuing collegial and collaborative dialogue in providing guidance to assist us in establishing the path forward to our resubmission for KRYSTEXXA," stated Paul Hamelin, President of Savient Pharmaceuticals. "We are grateful to the FDA for granting us this meeting so quickly and appreciate the considerable time and effort devoted by the FDA reviewers in evaluating our pre-meeting package and in providing very valuable feedback and guidance."

In response to the CRL, Savient requested and was granted the Type A meeting with the FDA to disc
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
2. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
7. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Savient Submits Biologics License Application (BLA) for pegloticase
9. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
10. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
11. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... Feb. 26, 2015  23andMe, the leading personal genetics ... as Privacy Officer and Corporate Counsel. Black brings ... laws as well as health care regulations. As a ... be responsible for reviewing, updating and enhancing the company,s ... and abroad. She joined the company January 5, 2015 ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... CAMBRIDGE, Mass., Feb. 6 Idenix,Pharmaceuticals, Inc. (Nasdaq: ... corporate overview at the upcoming BIO CEO & Investor,Conference ... in the Park Avenue,Suite Center/North Room at the Waldorf-Astoria ... archived webcasts of the presentation can be accessed,under "Calendar ...
... YORK, Feb. 6 Over the past few ... has become increasingly,apparent. Multinational interest and investment in ... and competition is heating,up. On one hand big ... offshoring. On the other hand, drug safety issues, ...
... Feb. 6 /PRNewswire-FirstCall/ - Diagnostic Imaging,International Corp. (OTCBB: DIIG) ... has been cleared for quotation on the OTC Bulletin,Board., ... Company announced today that the corporate website is,now live ... work diligently to build on its business plan as,quickly ...
Cached Biology Technology:Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials 2Diagnostic Imaging - New Stock Symbol - OTCBB: DIIG 2
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... the heat waves, heavy rains and droughts that climate change ... Speaking Wednesday at a contentious U.S. Senate hearing on ... offered a stark yet hopeful analogy. Just as speeding ... intensifies the risk of heat waves, droughts and heavy precipitation, ...
... Boulder, Colo., USA Two Geology studies focus on ... view of alpine denudation and the other studying and ... include fossil microatolls and sea level; the potential rupture ... Northwest and British Columbia; paleoclimate; and the relationship between ...
... 1, 2012) New research from Cornell University ... the third trimester of pregnancy may reduce the risk ... like high blood pressure and diabetes later in life.(i) ... Journal of the Federation of American Societies for ...
Cached Biology News:Stanford expert brings climate change science to heated Capitol Hill 2Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 2Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 3Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 4Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 5Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 6Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 7Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 8A diet high in choline during pregnancy may mean less stress for baby 2A diet high in choline during pregnancy may mean less stress for baby 3
Donor feline serum and plasma...
NPT1 (M-19)...
8 different frozen tissues are mounted on positively charged glass slides...
... Combining linear motor and ... offer pre-engineered Cartesian solutions that ... cable management, and motors., , ... , Pass through high-flex cabling ...
Biology Products: